Jenthera offers a novel cell targeted nuclease approach for therapeutics that addresses the fundamental challenges faced by CRISPR-based gene editing. Our approach has been independently validated to achieve high precision edits through unprecedented rates of HDR, is deliverable in vivo and addresses immunogenicity, safety and cost-effectiveness.